Business Context and Reporting Period
Company: Arrowhead Pharmaceuticals, Inc. (ARWR)
Filing Type: Form 8-K (Current Report)
Date of Report: September 10, 2025
Reporting Period: Event-based report regarding litigation filed on September 10, 2025.
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a legal event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the initiation of legal proceedings:
- Event: Filing of a Complaint for Declaratory Judgment.
- Defendant: Ionis Pharmaceuticals, Inc.
- Forum: United States District Court for the District of Delaware.
- Subject: Declaration that Ionis's U.S. Patent Number 9,593,333 (the "'333 patent") is invalid and/or not infringed by Arrowhead's planned commercialization of investigational plozasiran.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to vigorously pursue its claims in this litigation.
Forward-Looking Statements: The report contains statements regarding the planned commercialization of plozasiran, the merit of the Ionis letter, and the validity of the '333 Patent. These are based on current expectations and are subject to risks and uncertainties.
Risks: Actual results may differ materially from forward-looking statements due to factors described in the Company's most recent Form 10-K and 10-Q filings.
Investor Verification Checklist
- Review the attached Complaint for Declaratory Judgment (Exhibit 99.1) for specific legal arguments regarding the '333 patent.
- Assess the potential impact of this litigation on the commercialization timeline and strategy for plozasiran.
- Monitor subsequent filings for updates on the litigation status or any counter-claims by Ionis Pharmaceuticals.
- Refer to the most recent Form 10-K and 10-Q for comprehensive risk factors related to intellectual property disputes.